# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-50 of 564 results.
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Apr 07, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Biological samples collection
Locations: CHU Caen, Caen, France
Hopital Henri Mondor, Creteil, France
CHU Le Bocage, Dijon, France
CH Départemental, La Roche sur Yon, France
CHU Claude Hurriez, Lille, France
... and 11 other locations.
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 28, 2019
First Received: Sep 28, 2018
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): INCB053914, INCB050465
Locations: University of Arizona Cancer Center, Tucson, Arizona, United States
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
Clinical Research Alliance, Lake Success, New York, United States
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2)
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: Jun 04, 2020
Disease(s): Relapsed/Refractory Large B Cell Lymphoma
Intervention(s): ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Locations: Colorado Blood Cancer Institute, Denver, Colorado, United States
Moffitt Cancer Center, Tampa, Florida, United States
SCRI, Austin, Texas, United States
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: May 05, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
Locations: MorphoSys Research Site, Anaheim, California, United States
MorphoSys Research Site, Bakersfield, California, United States
Morphosys Research Site, Burbank, California, United States
Morphosys Research Site, Fresno, California, United States
MorphoSys Research Site, Los Angeles, California, United States
... and 154 other locations.
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Mar 13, 2019
First Received: Mar 13, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Pembrolizumab and CXD101
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: May 30, 2019
First Received: Dec 17, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): TQB2303, Rituximab
Locations: No.150 Haping Road, Nangang District, Haerbin, Heilongjiang, China
No. 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu, China
No.8 Jiangtan Road,Weibin District, Baoji, China
No. 87 Xiangya Road Furong District, Changsha, China
No.138 Tongzipo Road Yuelu District, Changsha, China
... and 27 other locations.
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: Feb 27, 2017
Disease(s): Diffuse Large B-cell-lymphoma
Intervention(s): Venetoclax, RICE
Locations: Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
CART-19 Cells for R/R B-cell Lymphoma
Status: Recruiting
Last Changed: Jan 05, 2018
First Received: Jan 05, 2018
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): CART-19 cells
Locations: Fujian Medical University Union Hospital, Fuzhou, Fujian, China
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 25, 2020
First Received: May 29, 2020
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Levine Cancer Institute - Clincal Trials Administration, Charlotte, North Carolina, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
UZ Gent, Gent, Belgium
... and 9 other locations.
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 17, 2020
First Received: Dec 02, 2019
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin
Locations: Memorial Regional Hospital, Hollywood, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States
Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States
... and 21 other locations.